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ABSTRACT 
Gliomas are known to be the most prevalent primary tumors of the central nervous system, of which 
glioblastoma is the most aggressive type with a median survival less than 2 years and no available 
cure. Studies in this thesis investigated the significance of two potentially important proteins in 
glioma biology, the transcription factor PROX1 and the histone chaperone NPM1, and the interplay 
of the therapeutic targets p53 and mTOR. 
Study I combined dataset mining and experimental studies to elucidate the function of PROX1 in 
glioblastoma. PROX1 mRNA was significantly lower in tumors with a mesenchymal signature, and 
its modulation in cultures derived from a heterogeneous glioblastoma tumor, transitioned the cells 
between non-mesenchymal and mesenchymal gene expression-based profiles. Concomitant with this 
were changes in proliferation rate, cell cycle proteins and stem cell markers. Further, the results 
revealed PROX1 regulation by SOX2, a connection that could be controlled by a CDK2 small 
molecule inhibitor. The findings from this study highlight the value of PROX1 as a prognostic tool 
and the functional role of PROX1 in glioma tumor development. 
In study II, immunohistochemistry analysis confirmed a significant overexpression of NPM1 in 
human glioblastoma samples. Moreover, the subcellular localization of NPM1 was assessed in 
glioma cell lines. NPM1 displayed a cloudy nuclear staining compared with the more pronounced 
nucleolar staining observed in normal cells. Moreover, NPM1 depletion altered the nucleolar 
structure, but had no major effect on cell viability. Interestingly, enforced expression of NPM1 
reduced apoptosis in histone H1.5 depleted cells, suggesting that NPM1 acts in a pro-survival 
manner in cells. 
In study III, the p53 response to drug-induced nucleolar stress and simultaneous inhibition of mTOR 
pathway by the use of various natural and synthetic compounds was analyzed. mTOR inhibition 
interfered with the p53 pathway stress response, as assessed by the impairment of p53 stabilization 
and reduced mRNA and protein levels of its downstream target p21. This provides information that 
may help improve combinatorial drug treatment regimens for cancer patients. 
Collectively, these studies provide novel insights into the biology of glioma brain tumors useful 
for patient diagnosis and more effective personalized therapies. 
 
Keywords: cancer, glioma, glioblastoma, nucleophosmin, PROX1, p53 pathway, mTOR pathway, 
nucleolar stress  
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1 INTRODUCTION 
 WHAT IS CANCER?   
Cancer is a generic term given to a group of related disorders, characterized by an aberrant 
mass of tissue growing excessively in an uncoordinated manner, and capacity to invade and 
impair adjacent tissue as well as different sites (Robbins & Cotran Pathologic Basis of 
Disease). According to the WHO, cancer accounts for the highest rate of death and 
morbidity in Europe (similar to the U.S.) after the cardiovascular diseases. Around 70% of 
cancer deaths take place in low- and middle-income countries, and it accounted for 8.8 
million deaths in year 2015 on a global scale (http://www.who.int/cancer/en/). It was 
reported that cancer burden has continued to grow with 6.6% increased mortality between 
2000 and 2015 in the European region, while countries such as Sweden, Switzerland and 
the United Kingdom have succeeded to reduce the mortality, showing that it is possible. 
Importantly, strategies for prevention, early detection, improved diagnosis and treatment 
could effectively reduce the mortality associated with cancer, as highlighted by the WHO 
(http://www.who.int/cancer/en/).  
Cancer cells divide abnormally, can infiltrate adjoining tissues and metastasize to other 
organs through the blood and lymphatic systems. Traditionally, cancers have been 
classified by their tissue type: Carcinomas are the most common malignancies and 
originate from the epithelial cells forming the skin or lining of the internal organs; 
sarcomas derive from cells of mesenchymal origin in the connective or supportive tissue 
such as bone, muscle, blood vessels or lymphoid tissues; leukemia could derive from 
blood-forming tissue like the bone marrow; lymphoma and multiple myeloma start in the 
cells of the immune system lymphocytes and plasma cells, respectively; melanomas 
originate from melanocytes of skin or eye, and cancers of the CNS arise from the cells of 
brain and spinal cord. 
It is widely believed that cancer cells display several abnormal properties including chronic 
proliferation signaling, bypassing growth suppressors, resisting apoptosis, enabling 
replicative immortality, activating angiogenesis, inducing invasion and metastasis 
(Hanahan and Weinberg, 2011). Additionally, reprogramming of energy metabolism and 
evading the immune system are considered in recent years among the cancer hallmarks 
(Hanahan and Weinberg, 2011). Indeed, a better knowledge about the capabilities of cancer 
cells will help the development of novel pathogenesis-based therapeutic strategies.  
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 ON THE ROAD TO CANCER 
Before cancer occurs, normal cells undergo multistep genetic, epigenetic and 
morphological alterations, which result in the formation of pre-malignant lesions. 
Hyperplasia is a pathology term describing an excessive cell proliferation while the cells 
still appear normal under the microscope, and dysplasia is referred to the stage when 
transformed cells look abnormal and the tissue disorganized, prior to the growth of a fully 
malignant lesion. Accumulating evidence suggests that tumorigenesis begins long before 
formation of clinically detectable lesions through “field cancerization” that refers to the 
evolution of normal somatic cells into cancer-primed cell populations, possessing the 
required underlying mutations and phenotypic predispositions such as chromosomal 
instability and mutation of TP53 gene (Curtius et al., 2018). Of note, these events can be 
initiated through exposure to mutagens and/or age-related mutations (Curtius et al., 2018). 
Additionally, chronic inflammation is viewed as a predisposition factor for the onset of 
cancer (Curtius et al., 2018). Therefore, it should potentially be possible to detect a 
“cancerized field” early on before the pro-tumorigenic mutations lead to selection and 
expansion of mutation carrying cells in surrounding ageing or inflamed but otherwise 
healthy tissue microenvironment (Curtius et al., 2018), which in turn could result in 
increased lifespan through preventive measurements. 
The cancer stem cell (CSC) hypothesis has remained work in progress, and postulates an 
intra-tumoral hierarchy, where a small fraction of cancer cells exhibits higher self–
renewal capacity and pluripotency that is required for tumorigenesis (Reya et al., 2001; 
Stiles and Rowitch, 2008; Tan et al., 2006). This “stemness”, combined with an enhanced 
capacity for invasion and notorious resistance to therapy bestows a deadly triad that links 
such cell population to poor outcome for the cancer patient.   
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 GLIOMA BRAIN TUMORS 
Malignant CNS tumors represent the deadliest cancers considering the years of potential 
life lost post diagnosis, with estimated mean of ~20 years (Rouse et al., 2016).  Gliomas 
are the most common type of primary intracranial tumors, which comprise about 80 
percent of all malignant brain tumors and have largely unknown etiology (Goodenberger 
and Jenkins, 2012; Ostrom et al., 2014; Reifenberger et al., 2017). While gliomas can 
occur anywhere in the CNS they generally arise from the glial tissue in the brain (Ostrom 
et al., 2014). 
These complex ecosystems of different cell types were previously classified merely based 
on histological criteria and degree of anaplasia from slow-growing principally benign 
grade-I lesions usually associated with a favorable prognosis to grade-IV tumors, also 
known as glioblastomas, which represent the most aggressive primary brain tumor in 
adults (Furnari et al., 2007). The international classification of CNS tumors by WHO was 
recently revised to incorporate molecular biomarkers such as IDH1/2 status, MGMT-
promoter methylation, and 1p/19q co-deletion identified by genome-wide molecular 
profiling efforts with neuropathological diagnosis based on histological features, i.e. the 
WHO grade and type (Reifenberger et al., 2017). Therefore, the revision aims to 
implement molecular diagnosis and thereby precision medicine in neurooncology by 
defining distinct tumor entities as precisely as possible leading to improved patient 
outcomes (Reifenberger et al., 2017).  
1.3.1 Glioma WHO grade-IV (glioblastoma)  
Glioblastomas are the most devastating and common gliomas (∼45% of all gliomas), 
which to date have remained associated with extremely aggressive clinical courses and 
only 0.05% to 4.7% of patients surviving 5 years following diagnosis (Ostrom et al., 
2014).  
In effect, glioblastoma classification includes a spectrum of biologically distinct tumors 
having different age of onset, tumor location and prognosis. Microscopically, these 
tumors are often presented with nuclear atypia and cellular pleomorphism, high mitotic 
activity, as well as pseudopalisading necrotic areas and microvascular proliferation that 
distinguish them from the gliomas of lower grades (Hambardzumyan and Bergers, 2015).  
In particular, the high degree of histopathological diversity and inter- and intrapatient 
tumor heterogeneity poses several obstacles for understanding the disease, and improved 
diagnosis and treatment regimens.  
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A major obstacle in glioblastoma treatment is the diffuse tumor infiltration/invasion into 
the surrounding healthy tissue in characteristically distinctive patterns known as Scherer's 
structures, resembling threads of a spider’s web, which enables them to escape complete 
surgical resection and chemo- and radiation therapy (Cuddapah et al., 2014). Despite a 
challenge posed by the brain’s limited extracellular space, glioma cells are thought to gain 
mobility and collectively use existing brain structures such as nerve tracts and blood 
vessels to invade nearby tissue. Additionally, the conditions of pro-tumoral inflammation 
and/or EMT in the extracellular matrix can make way for cancer cells, facilitating tumor 
invasion (Cuddapah et al., 2014; Noroxe et al., 2016).   
At present, the standard of care for most glioblastomas can extend patients’ lives by about 
a year (15-17 months median survival in contemporary clinical trials), and tumors 
eventually recur after multimodal treatments (Furnari et al., 2007; Stupp et al., 2009). The 
treatment for newly diagnosed cases include maximal resection followed by radiotherapy 
and/or 6 cycles of adjuvant chemotherapy with Temozolomide (Stupp et al., 2005). 
Notably, the common risks for detrimental impact on neurological and cognitive 
functioning of the patients should be considered, which could hinder complete surgical 
removal of the tumor.  
However, molecular neuropathology has shown promise for better diagnosis of the 
tumors, and incremental improvements in survival are anticipated with the therapeutics in 
development. 
The advent of large-scale genomic and epigenomic studies has provided deeper insights 
into molecular pathology of gliomas and identified novel targets for therapy such as the 
mutant IDH1 enzyme (Brennan et al., 2013b; Parsons et al., 2008; Sturm et al., 2014; 
TCGA, 2008; Verhaak et al., 2010). Based on DNA and RNA profiling of bulk tumors 
and identified aberrations in EGFR, NF1, PDGFRA and IDH1, glioblastomas were 
clustered into four main subtypes: proneural (PN), neural (N), classical (CL), and 
mesenchymal (MES) (Brennan et al., 2013a; TCGA, 2008; Verhaak et al., 2010). The 
glioblastoma-associated genetic changes validated in these studies distinguish three core 
signaling axes: (I) p53 pathway, (II) receptor tyrosine kinase (RTK)/phosphatidylinositide 
3-kinase (PI3K)/Ras pathway, and (III) retinoblastoma (Rb) signaling. Interestingly, the 
profiling based glioblastoma subtypes also bear resemblance to gene expression profiles 
of normal brain cells; for a review regarding glioma genetics and biology please see 
(Alcantara Llaguno and Parada, 2016). 
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Furthermore, general advancements in tumor biology and especially in the area of tumor 
microenvironment research have led to the development of novel targeted therapies 
(Bielen et al., 2011; Dresemann, 2005), including cutting-edge immune-based treatments 
such as dendritic cell vaccines, which are currently undergoing evaluation and/or 
optimization for glioblastoma. Dendritic cells are the most robust antigen presenting cells, 
which could be engineered for enhanced recognition of tumor cells by patients’ immune 
system and activate a long-lasting response for their elimination. Another immune-based 
approach advancing to late-stage clinical trials for glioblastoma patients exploits 
checkpoint inhibitor drugs, developed to block tumor cells blunting of the immune 
response. Finally, identification of novel technologies and better prognostic biomarkers 
linked to tumor growth and metabolism for the assessment of treatments is focus of 
intense investigation.   
1.3.2 Glioma biology – stem cells in focus  
Glioma biology is complex, and gliomagenesis involves processes that recapitulate CNS 
development with dynamic regulation and plasticity in cell populations within the 
heterogeneous tumor tissue. In other words, defined neurodevelopmental programs in 
normal stem and progenitor cells of the brain could re-emerge in “glioma stem cells” 
(GSCs) during tumorigenesis. It is thought that the activation of stem cell regulatory 
programs accounts for maintenance of the tumor under stress conditions, and likely 
enhances tumor growth, resistance to therapy, invasion, and angiogenesis (Bao et al., 
2006; Singh et al., 2004a; Singh et al., 2003). Thus, the GSCs are important in glioma 
research and they are increasingly viewed as legitimate therapeutic targets (Altaner, 2008; 
Hambardzumyan et al., 2008).  
Cancer stem cells were initially identified in brain tumors by their expression of the neural 
stem cell surface marker CD133 (Singh et al., 2003), and while high expression of genes 
such as SOX2, NESTIN, OCT4, KLF4, NOTCH1, and GFAP has been repeatedly 
associated with stem/progenitor cells in the glioblastoma literature, none of these markers 
is able to define the GSCs alone. Recently, glioma stemness was linked to a core set of 
four master transcription factors: SALL1, POU3F2 (OCT7), OLIG2 and SOX2, that 
were proposed to contribute to tumor progression and underlie therapeutic resistance 
(Suva et al., 2014).  
Of note, the effects of EMT programs on stemness features, cell proliferation and survival 
has linked it to tumorigenesis (Brabletz et al., 2018). During EMT, polarized epithelial 
cells progressively change morphology and biochemical characteristics to acquire a more 
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mesenchymal phenotype. As crucial mediators of cellular plasticity supporting tumor 
progression, the EMT-activating transcription factors (EMT-TFs) have been associated 
with poor clinical outcome in many cancer types of both epithelial and non-epithelial 
origins (Brabletz et al., 2018). A common source of confusion regarding the EMT term in 
cancer biology arises from the frequent expression of EMT-TFs in non-epithelial tumors 
including gliomas (Brabletz et al., 2018). EMT is not a uniform biological process defined 
by one single pathway, and the EMT-TFs such as SNAIL, SLUG, TWIST and ZEB 
families have other non-redundant and tissue-specific roles (Brabletz et al., 2018). 
Nevertheless, the divergent tumorigenic events involved in EMT result in more similar 
phenotypic endpoints and a generic gene expression signature was recently proposed to 
score EMT status amongst clinical samples (Tan et al., 2014). Using this generic signature 
for EMT or proneural-to-mesenchymal transition (PMT) – a term increasingly recognized 
in the glioblastoma literature, it was established that glioblastoma tumors (and cell lines) 
were primarily mesenchymal, and that patients with proneural tumors displayed better 
overall survival (Jiang et al., 2017; Patel et al., 2014).  
Although not fully elucidated, EMT/PMT in glioblastoma is generally associated with a 
hypoxic tumor microenvironment, inflammation, enrichment of macrophages/microglia, 
and activation of signaling pathways such as SNAIL, NF1, and NF-kB (Iwadate, 2016). 
Intriguingly, a study from Moustakas laboratory revealed that Snail overexpression in 
glioblastoma cells increased tumor invasiveness in a mouse xenograft model, while it 
depleted the gliomasphere formation capacity in vitro and pluripotency and tumor 
growth in vivo (Savary et al., 2013). Another recent study established that immunological 
changes in a microenvironment enriched with macrophage/microglia induce proneural to 
mesenchymal transition in glioblastoma cells, as previously reported through NF-kB 
activation (Bhat et al., 2013) – but it also revealed that genetic inactivation of NF1 drives 
chemo-attraction of tumor-associated macrophages/microglia, pointing to an interplay 
between tumor cells and their microenvironment during EMT (Wang et al., 2017). 
Finally, a mesenchymal shift could be triggered by radiation exposure in vivo (Halliday et 
al., 2014) and since mesenchymally transitioned cells are more radio-resistant (Bhat et al., 
2013) it could impact the effectiveness of radiotherapy (Halliday et al., 2014). 
Collectively, the GSCs are thought to arise from adult neural stem cells or multipotent 
neural progenitor cells that persist in proliferative niches in the human CNS found for 
instance in the SVZ, or alternatively, from differentiated lineages such as astrocytes 
(Stopschinski et al., 2013) or oligodendrocyte progenitors. Experimentally, these cells can 
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be modeled to grow as spheres in vitro (similar to neural stem cells), and have been 
inferred the capacity to initiate tumors and recapitulate histology of the initial tumor in 
animal models (Chen et al., 2012; Singh et al., 2003; Singh et al., 2004b). Another report 
revealed that glioblastoma single cell transcriptomes (Patel et al., 2014) correlate with 
those of the normal outer radial glia, i.e. outer subventricular zone glia niche of neural 
stem cells of the neocortex (Pollen et al., 2015). Specifically, the transcriptional signatures 
of the outer radial glia cells were enriched in cells from primary glioblastomas, pointing 
to common sets of genes that control self-renewal (and migration) in the healthy 
developing brain and tumor tissues (Pollen et al., 2015). More recently, a landmark study 
proposed that intratumoral heterogeneity in glioblastoma is the expected outcome of fate 
decisions made by GSCs and their progeny, independent of an evolving mutational 
signature (Lan et al., 2017). The authors studied clonal evolution by following serial 
xenotransplantation of barcoded glioblastoma cells to map their individual fate, and found 
a hierarchy defined by proliferative activity, in which slow-growing stem-like cells evolve 
into progenitor cells with enhanced proliferation rate and capacity for self-maintenance, 
that in turn bring about more quiescent cells (Lan et al., 2017). 
1.3.3 Molecular biomarkers of glioma – an ongoing challenge  
As noted earlier, determination of a number of molecular biomarkers such as IDH1/2 
mutations, 1p/19q co-deletion, MGMT promoter methylation, and EGFRvIII 
amplification could be useful in routine clinical practice, in accordance with the recently 
revised WHO guidelines. Of note, a preceding practical framework classified gliomas into 
five groups based on IDH mutations, 1p/19q co-deletion and TERT promoter mutations, 
and suggested incorporation of TP53, EGFR, or PTEN among other alterations for the 
refinement of glioma diagnosis (Eckel-Passow et al., 2015).  
An important advancement in the recent classification of glioma entities is related to the 
IDH mutation status found among low- and intermediate-grade gliomas (mostly WHO 
grade II and III) (Parsons et al., 2008; Yan et al., 2009). IDH1 and IDH2 are key enzymes 
involved in cellular energy metabolism. IDH1 mutations were identified in a large 
fraction of young patients and in most patients with secondary glioblastomas, associated 
with significantly better overall survival (Parsons et al., 2008). In brief, IDH mutation is 
tightly associated with an aberrant DNA and histone methylation profile that leads to 
widespread hypermethylation of CpG islands, termed ‘glioma-CpG island methylator 
phenotype’ (G-CIMP) (Noushmehr et al., 2010).  
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Of note, methylation of the MGMT promoter has a prognostic value in anaplastic grade III 
tumors, and can predict whether patients with IDH-wild-type glioblastoma would benefit 
from alkylating chemotherapy with Temozolomide (Stupp et al., 2014). Furthermore, co-
deletion or loss of heterozygosity on chromosomes 1p/19q could be used for the diagnosis 
of oligodendroglioma entity, generally associated with both MGMT promoter methylation 
and IDH mutation, and distinguished from tumors of astrocytic lineages for example by 
an assessment of their wild type TP53 status (Stupp et al., 2014). Additionally, the 1p/19q 
co-deletion has predictive value for chemotherapeutic response in oligodendrogliomas.  
Table 1 summarizes the expected survival of gliomas; adapted from Stupp et al., ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up (Stupp et al., 2014). 
 
 
 
 
It is anticipated that novel techniques for the analysis of DNA methylation, copy number 
variations and mutational profiling by next generation sequencing (NGS) will lead to 
defining and developing better biomarkers, which pave the way for improved patient 
selection and treatment response in the era of precision medicine in neuro-oncology.  
 
Grade and cell type Median survival  
Grade II  
Astrocytoma 7–10 years 
Oligodendrogliomaaa  >10–15 years 
Grade III  
Anaplastic astrocytoma  3.5 years 
Anaplastic 
oligodendrogliomaaa  
>10 years  
Grade IV 
Glioblastoma 15 months, 2-year survival 27% 
MGMT 
Methylated 23 months, 2-year survival: 49% 
Unmethylated 13 months, 2-year survival: 12%  
a With LOH 1p/19q. MGMT, methyl-guanine methyl transferase 
Table 1. Expected survival of glioma (Stupp et al., 2014) 
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  PROX1 IN NORMAL DEVELOPMENT AND CANCER 
Prospero-Related Homeobox 1 (PROX1) has emerged in recent years as a key factor in 
developmental biology and implicated in several cancers including gliomas, which is the 
main focus of this thesis work. 
1.4.1 PROX1 in development  
PROX1 is localized on chromosome 1q32.2-q32.3, and encodes a transcription factor 
comprised of two domains, an “atypical” homeodomain and a conserved Prospero 
domain (Zinovieva et al., 1996), each contributing to its specific binding to DNA, for a 
review about PROX1 see (Elsir et al., 2012). The N-terminal part of this 83kDa protein 
harbors a nuclear localization signal and two nuclear receptor boxes (NR-boxes) (Elsir 
et al., 2012). The homeobox protein Prospero in Drosophila mediates transcriptional 
repression of stem cell genes and activation of differentiation genes, thereby 
counteracting tumorigenesis (Betschinger et al., 2006; Doe et al., 1991; Freeman and 
Doe, 2001; Hirata et al., 1995; Knoblich et al., 1995; Li and Vaessin, 2000). 
Specifically, Prospero is required in the ganglion mother cells (GMC) to carry out three 
main functions: to activate neuronal differentiation genes in the larval brain, repress 
genes specific for neuroblasts, and repress the cell cycle genes (Doe et al., 1991; 
Freeman and Doe, 2001; Hirata et al., 1995; Knoblich et al., 1995; Li and Vaessin, 
2000). In mouse, Prox1 has been found essential in several aspects of morphogenesis 
and embryonic development of different organs including lymphatic, hepatocyte, 
pancreatic, heart, lens, and the central nervous system (CNS) (Elsir et al., 2012; Risebro 
et al., 2009; Seth et al., 2014; Sosa-Pineda et al., 2000; Wigle et al., 1999; Wigle and 
Oliver, 1999). Also, Prox1 contributes to physiological control of stem and progenitor 
cells in the developing and adult brain (Elsir et al., 2012). Accumulating evidence from 
developmental studies has indicated the importance of WNT signaling in NSC self-
renewal and proliferation (Clevers et al., 2014; Kalani et al., 2008), and Prox1 is a 
downstream target for the canonical Wnt signaling in adult hippocampal neurogenesis 
(Karalay et al., 2011). Prox1 was also reported to suppress Notch1 expression, 
controlling the balance between self-renewal of neural progenitor cells and neuronal 
differentiation (Kaltezioti et al., 2010).  
PROX1 has been reported as part of important transcription factor complexes/networks 
in several independent studies (Elsir et al., 2012). Accumulating evidence points to 
Prox1 involvement in regulation of energy homeostasis, metabolism and circadian 
rhythms in the liver where it forms complexes with HDAC3, BMAL1, ERRα and PGC-
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1α (Charest-Marcotte et al., 2010; Dufour et al., 2011; Steffensen et al., 2004). Recent 
studies revealed that an HDAC3-PROX1 corepressor module acts on HNF4α to control 
hepatic triglycerides (Armour et al., 2017; Kwon et al., 2016). Further, Prox1 was found 
to co-regulate the rhythmic control of metabolic outputs and the metabolic gene 
networks by interacting with ERRα, and PGC-1α, through binding to the promoters of 
metabolic genes and blocking ERRα/PGC-1α complex activity (Charest-Marcotte et al., 
2010; Dufour et al., 2011). PGC1-α is a known regulator of mitochondria biogenesis and 
expressed at high levels in tissues with high metabolic demands (e.g. heart, skeletal 
muscle, kidney and brain) (Austin and St-Pierre, 2012). Of particular interest, PGC-1α is 
also expressed in the developing brain and involved in metabolism and/or survival of 
GABAergic neurons (pertaining to or affecting the neurotransmitter GABA) (Cowell et 
al., 2007). Intriguingly, preliminary results from gene expression and immunoblotting 
analysis of U-343 glioblastoma cell cultures performed in our laboratory implicates 
PROX1 in regulation of PPARGC1A/PGC1α levels, connected with corresponding 
changes in the mitochondrial morphology (Goudarzi KM et al., unpublished data), 
which merits further investigation. Finally, PROX1 is also involved in glucose 
metabolism and large-scale meta-analyses of genome-wide association studies 
confirmed that the rs340874 single-nucleotide polymorphism in PROX1 is linked to 
fasting glycemia as well as type 2 diabetes mellitus (Kretowski et al., 2015; Lecompte et 
al., 2013). 
1.4.2 PROX1 in cancer  
PROX1 has been shown in several instances to be involved in cancer development (Elsir 
et al., 2012). Depending on the context, PROX1 has both been suggested to have tumor 
suppressive capacity and be involved in tumor progression. PROX1 was associated with 
suppression of neuroblastoma cells, possibly by inhibition of Cdc25A and induction of 
p27-Kip1 to counteract Cyclin E1 overexpression (Foskolou et al., 2013). However, 
PROX1 enhanced colorectal cancer progression, and it may promote cell proliferation 
(Petrova et al., 2008). The same report indicated PROX1 as a Wnt-beta-catenin-
TCF/LEF target in colon adenomas, contributing to the transition from an early to 
dysplastic stage (Petrova et al., 2008). Connected to this, Prox1 was found to regulate 
the number of stem cells via cell proliferation to promote expansion of the stem cell 
population in intestinal adenomas and colorectal cancer after activation of the Wnt 
pathway, and that the effects were mediated by Annexin A1 and Filamin A (Wiener et 
al., 2014).  
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Hypermethylation of PROX1 has been reported to occur in breast cancer and 
lymphomas and in brain metastases of breast cancer (Laerm et al., 2007) (Nagai et al., 
2003; Versmold et al., 2007). Moreover, mutations of PROX1 and loss of heterozygosity 
have been reported in a few cancers (Laerm et al., 2007) (Nagai et al., 2003; Takahashi 
et al., 2006; Versmold et al., 2007; Yoshimoto et al., 2007). 
PROX1 was previously detected by immunohistochemistry in human astrocytic brain 
tumors with increasing levels correlating with higher WHO grade (Elsir et al., 2010), 
and may therefore constitute a useful tool for the diagnosis and grading of gliomas to 
distinguish low-grade diffuse lesions (grade II) from high-grade (grades III–IV) 
malignancies. Furthermore, the authors proposed PROX1 as a novel predictor of 
survival for grade II astrocytic gliomas, where high level of PROX1 was associated with 
poor outcome (Elsir et al., 2012). More recently, PROX1 was suggested as a useful 
pathway-specific prognostic biomarker in case of high-grade astrocytomas (Roodakker 
et al., 2016). While no correlation was found between PROX1 and survival for patients 
with primary glioblastomas, higher presence of the protein predicted shorter survival 
times corresponding to the groups of 1p19q non-codeleted high-grade astrocytomas that 
have progressed from pre-existing low-grade tumors with an IDH mutation (Roodakker 
et al., 2016).   
These studies raise the question of functional significance of PROX1 expression in 
glioma cells, and the cellular signaling pathways it could regulate. PROX1 may function 
in glioma initiation and progression by several mechanisms: (a) PROX1 acts as a key 
regulator of macro-metastatic lesions in colon cancer outgrowths by promoting 
adaptation of tumor cells to hypoxia and nutrient deprivation (Ragusa et al., 2014) and 
high grade gliomas are notoriously hypoxic, hence PROX1 could be a survival factor in 
human gliomas. (b) PROX1 modulates cell proliferation and differentiation in several 
cellular systems, including CNS and may therefore also have such impact in glioma. A 
subpopulation of Prox1+ colon cancer cells were shown to display cancer stem cell 
features (Wiener et al., 2014). Prox1 depletion led to fewer stem cells and reduced cell 
proliferation, and decline in intestinal tumor growth via induction of Annexin A1, and 
reduced level of the actin-binding protein known as Filamin A. PROX1 is therefore 
involved in regulating stem cells, a feature that have been shown to be important in 
glioblastoma cell. (c) PROX1 regulates the migration and/or tissue invasion of certain 
cell types (Dadras et al., 2008; Elyada et al., 2011), and it is known that glioma cells are 
highly invasive and migratory. 
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 RIBOSOME BIOGENESIS: AN ACHILLES’ HEEL OF GLIOMA?  
Cancer is characterized by a mass of cells growing and proliferating in a haphazard way 
(Hanahan and Weinberg, 2011), and cancer cells – with their high metabolic demands, 
need to couple their extensive protein production and accumulation of mass and size with 
the subsequent divisions to daughter cells. It is thought that bioenergetic pathways are 
connected to oncogenic drivers in glioma. For instance, the mTOR pathway may provide 
metabolic flexibility and boost survival of the glioma cells (Strickland and Stoll, 2017).  
A vast amount of research efforts has therefore focused on energy metabolism, protein 
synthesis and cell cycle control in tumor cells to exploit their vulnerabilities and open 
therapeutic avenues (Strickland and Stoll, 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 | Ribosome biogenesis: the essentials. Adapted from (Pelletier et al., 2018), with permission.  
 
Ribosomes are central to life as the sites of protein synthesis required for proper cell 
growth and proliferation, and they are composed of many distinct proteins and nucleic 
acids. Ribosome biogenesis is elaborate, multifaceted, and a massively energy consuming 
process that demands the function of all three RNA polymerases and an army of non-
ribosomal factors for the ribosomal RNA (rRNA) synthesis, maturation and assembly into 
small and large subunits in a highly coordinated manner (Pelletier et al., 2018). In brief, 
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the two pre-subunits pre-40S (containing 18S rRNA and 33 distinct ribosomal proteins) 
and pre-60S (5S, 5.8S and 28S rRNA) are assembled in the nucleolus (Figure 1) (Pelletier 
et al., 2018). This process is initiated by the RNA polymerase I (Pol I) transcription of 
47S precursor rRNAs from ribosomal DNA (rDNA) genes, and its assembly into 90S 
processome together with 5S rRNA. These are subsequently exported to the cytoplasm 
completing their final maturation steps, forming the mature 80S ribosome, which begins 
the manufacturing of proteins (Figure 1) (Pelletier et al., 2018).  
Recent molecular profiling studies have identified mutations in genes that encode RPs 
(Goudarzi and Lindstrom, 2016). Specifically, the RPL5 gene was reported to contain 
truncating mutation in glioblastoma and other cancer types (Lawrence et al., 2014). 
Moreover, a number of human disorders linked to dysregulated ribosome biogenesis and 
function such as Diamond-Blackfan anemia (DBA) – collectively ribosomopathies, are 
associated with single-copy loss of function mutations in genes encoding specific RPs, or 
in other cases defects in ribosome biogenesis factors (Goudarzi and Lindstrom, 2016; 
Mills and Green, 2017). Intriguingly, these patients are known to be at higher risk for 
developing cancer.  
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 THE NUCLEOLUS IN A “NUTSHELL” 
Nucleoli are dynamic nuclear compartments around nucleolar organizer regions (NORs), 
where biogenesis of ribosomes take place, and they are composed of three structural 
compartments: the fibrillar centers (FC) and dense fibrillar centers (DFC), where 
transcription and processing occur, and the granular component (GC) that is the site of 
pre-ribosome assembly (Figure 1) (Pelletier et al., 2018; Raska et al., 2006). As early as in 
the 19th century, increased number, enlarged size, and irregular morphology of nucleoli 
have been used to distinguish cancer cells from the normal cells in tumor tissues, and a 
large body of evidence has indicated nucleolar irregularities as a prognostic marker 
associated with tumor aggressiveness (Goudarzi and Lindstrom, 2016; Ruggero, 2012). 
Apart from their main role as ribosome-producing factories, the nucleoli have emerged in 
recent years as the central regulatory hub for coordinating genomic organization and the 
maintenance of genome integrity, cell cycle control, the cellular responses to a wide 
variety of environmental signals and the quality control for RNA and protein production 
(Grummt, 2013; Lindstrom et al., 2018). As cellular stress sensors, it is believed that the 
nucleoli transmit genotoxic, metabolic, transcriptional and other types of stresses to the 
cell fate gatekeeper p53, through so called “ribosome biogenesis surveillance” pathway 
that involves NPM1 and other nucleolar factors (Lindstrom et al., 2007).  
Given these observations, nucleolar proteins are under intensive investigation for their 
potential involvement in multiple types of cancer, including glioma, and nucleoli could be 
promising target for cancer therapeutics (Goudarzi and Lindstrom, 2016; Ruggero, 2012). 
 
  
   21 
 NPM1 IN NORMAL CELL BIOLOGY AND CANCER  
1.7.1 NPM1 as a stress sensing nucleolar chaperone 
The ubiquitously expressed NPM1 (also known as B23, NO38, or nucleophosmin) is a 
multifunctional non-ribosomal phosphoprotein, prominently localized in the nucleoli, and 
involved in normal cellular processes such as ribosome biogenesis, mRNA transport, 
genome stability and apoptosis (Box et al., 2016). NPM1 is evolutionary conserved and 
consists of 12 exons (NPM1.1 and NPM1.3 are splice variants), encoding the 37kDa 
phosphoprotein Nucleophosmin 1 found in all Metazoan. The members of NPM family 
(NPM1-3) share common structural motifs: a core domain at the N-terminal, an acidic 
domain and a nuclear localization signal at the C-terminal part of the protein (Box et al., 
2016).  
It has been reported that NPM1 function is required for p53 stabilization in the nucleus by 
inhibiting p53:MDM2 interaction following UV-induced DNA damage (Colombo et al., 
2002; Kurki et al., 2004). Moreover, NPM1 can directly interact with p53 to regulate its 
transcriptional activation induced by various stressors, and specifically was shown to 
induce a p53-dependent premature senescence upon its overexpression in diploid 
fibroblasts (Colombo et al., 2002).  
 
1.7.2 NPM1 in cancer  
Studies in recent years have underscored NPM1 function both as an oncogene and a 
tumor suppressor. Of note, reports show NPM1 mutations in leukemia and lymphoma, its 
overexpression in solid tumors, and rearrangements in different types of cancers (Box et 
al., 2016; Holmberg Olausson et al., 2015). It is believed that abundant NPM1 contributes 
to chromatin stability, functional rDNA transcription and ribosome biogenesis, while 
decreased levels result in genome instability and impairment of p53 stabilization.  
NPM1 overexpression has also been reported in glioma tissue and cell lines (Chen et al., 
2015). In the tumor tissues, NPM1 expression was correlated with Ki-67 index and the 
pathological grades, therefore it was suggested as a determinant of poor prognosis (Chen 
et al., 2015).  
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 THE EMERGING RIBOSOMAL PROTEIN-MDM2-P53 AXIS 
1.8.1 p53 tumor suppressor  
 
The transcription factor p53 is a tumor suppressor that responds to a broad range of 
stress signals by orchestrating specific cellular responses which span from induction of 
a transient (cell cycle arrest) or permanent (senescence) blockade of cell proliferation to 
apoptosis (Bieging et al., 2014). Moreover, by integrating the activity of metabolite-
sensing pathways, p53 participates in the management of cellular metabolism during 
nutrient and oxygen stress (Humpton and Vousden, 2016).  
 
 
 
A wide variety of regulators govern the activity of p53 (Figure 2, top), which, in turn, 
coordinates many distinct biological processes (Figure 2, bottom); reviewed in 
(Kastenhuber and Lowe, 2017). These cancer-associated stress stimuli include DNA 
damage, oxidative stress and hypoxia, as well as hyper-proliferative signals and nutrient 
starvation. Thus, p53 inactivation is considered a pivotal event in the tumorigenic 
Figure 2. The p53 Network. Adapted from (Kastenhuber and Lowe, 2017), with permission.   
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outgrowth, and more than half of all sporadic tumors have an inactivated p53 pathway. 
It is also known that individuals with a hereditary genetic condition called Li–Fraumeni 
syndrome (LFS) who inherit a mutant TP53 allele are predisposed to a wide range of 
cancers at young age, pointing to the significance of a functional p53 protein in tumor 
suppression (Bieging et al., 2014).   
On the other hand, a growing number of studies in recent years have underscored non-
canonical functions of p53 in control of other cellular processes including stem cell 
maintenance, cell–cell communication within the tumor microenvironment, and cell 
metabolism, which could also contribute to tumor suppression (Bieging et al., 2014). In 
the developing and adult CNS, p53 functions are implicated in self-renewal of neural 
precursor cells, differentiation, and cell fate decisions. It is believed that p53 can 
suppress self-renewal of neural stem cells (Meletis et al., 2006), promote differentiation, 
and thus limit tumorigenesis by inhibiting characteristics of 'stemness' (Bieging et al., 
2014). Specifically, it was revealed, through studies of (CNS)-specific Trp53−/−Pten−/− 
mice, that p53 and PTEN together restrict neural and glioma stem/progenitor cell 
renewal, promote differentiation and inhibit glioblastoma development (Bieging et al., 
2014; Zheng et al., 2008). It was therefore proposed that p53 could inhibit 
tumorigenesis through suppression of stemness characteristics (Bieging et al., 2014).   
Together, an elucidation of p53’s physiological functions as well as p53-mediated tumor 
suppression can pave the way for earlier diagnosis, prognostication, and anti-cancer 
therapy (Bieging et al., 2014).   
1.8.2 The mTOR pathway  
Increased growth and proliferation is one of the hallmarks of cancer and is often achieved 
by exploitation of the mTOR pathway to globally upregulate protein synthesis and even 
boost the process of ribosome biogenesis itself. Therefore, it is commonly assumed that 
targeting such dependency in malignant cells can be an effective strategy against cancer 
development.   
The mTOR pathway is the key integrator of intercellular signals and environmental 
stimuli such as stress and availability of growth factors and nutrients. Thereby, it is 
important in the regulation of cell cycle as a modulator of anabolic versus catabolic 
processes. Specifically, the crucial role of the mTOR pathway in regulating cell growth 
and metabolism has connected its inhibition to the protection against aging and its 
dysregulation to human diseases including cancer. This significance has attracted great 
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scientific interest in understanding mTOR signaling, as well as clinical interest in the 
development of mTOR inhibitors (mainly rapamycin derivatives or rapalogs), for the 
purpose of targeting mTOR in several solid malignancies including glioblastomas. 
Therefore, rapalogs such as CCL-779 (Temsirolimus) have been tested in clinical trials, 
although with limited efficacy to date (Strickland and Stoll, 2017).  
Of the two existing multiprotein complexes mTORC1 and mTORC2, the better-known 
mTOR1 is connected to mRNA translation and protein synthesis, and found upregulated 
in most cancers (Gentilella et al., 2015). It is believed that ribosome biogenesis and 
protein synthesis are induced following growth stimulating cues, through mTORC1 
phosphorylation of its cellular targets RPS6 kinases (S6K1/2) at Thr389 and the protein 
initiation factor 4E binding proteins (4E-BP1/2/3) at Ser65 (Gentilella et al., 2015; 
Strickland and Stoll, 2017). Moreover, the mTORC1 complex is involved in lipid 
biosynthesis, as well as in regulation of glucose metabolism and mitochondrial function 
(Gentilella et al., 2015). However, the precise molecular mechanism of mTOR signaling 
is still not elucidated. 
In addition to p53-independent mTOR1 functions, a large body of evidence in recent 
years has pointed to its crosstalk with the p53 pathway in control of cell fate 
determination through a number of mechanisms.   
1.8.3 The concept of “nucleolar stress” 
It is well established that disruption of ribosome biogenesis or nucleolar structure – also 
known as “ribosomal stress” or “nucleolar stress” could lead to stabilization of the p53 
protein. However, mechanisms behind this p53 activation are not fully elucidated, and it 
is debated whether involvement of the nucleolus in p53 stabilization is indirect or direct 
(Deisenroth and Zhang, 2010). 
The nucleoli are proposed as cellular compartments where p53 regulation occurs (Boyd et 
al., 2011). Specifically, this model suggests a direct involvement of the nucleolus in 
catalyzing p53 protein degradation via its ubiquitylation and transport, which is perturbed 
following nucleolar stress (Boyd et al., 2011).  
Another model with substantial amount of both in vitro and in vivo experimental support 
is based on the re-localization of diffusible components that can disrupt the p53-MDM2 
interaction.  
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More specifically, under normal conditions, the pre-ribosomal complex 5S RNP, 
consisting of the 5S rRNA RPL5, and RPL11, is incorporated into nascent 60S 
ribosomes in the nucleolus, and p53 is degraded through the E3 ubiqutine ligase activity 
of MDM2. However, following a disruption of ribosome biogenesis, the 5S RNP, also 
recently referred to as ‘impaired ribosome biogenesis checkpoint (IRBC) complex’, is re-
distributed from the assembly into newly synthesized 60S ribosomes in the nucleoli to the 
binding of MDM2, leading to p53 activation and possible suppression of tumorigenesis 
(Pelletier et al., 2018; Sloan et al., 2013). Therefore, a crucial consequence of ribosomal 
stress and 'IRBC response' could be p53-mediated cell cycle arrest and apoptosis (Mills 
and Green, 2017; Pelletier et al., 2018). In this model, cancer cells having higher levels of 
protein synthesis are more sensitive to the perturbations of ribosome biogenesis 
(Lindstrom et al., 2007; Mills and Green, 2017).  
Many commonly used anti-cancer drugs interfere with DNA replication or block RNA 
pol I and RNA pol II transcription targeting dividing cells. A few compounds that induce 
nucleolar stress have shown some rather promising effects on glioma-derived cells with 
stem-like properties in vitro. Examples of drugs that target ribosome biogenesis include 
low concentrations (<10nM) of Actinomycin D, which intercalates in GC-rich region of 
rDNA and preferentially inhibits RNA Polymerase I activity and induces p53 through the 
nucleolar stress pathway (Macias et al., 2010). Other examples include cisplatin that 
crosslinks DNA and hijacks UBF, therefore also inhibiting RNA pol I at low 
concentrations, whereas 5-Fluorouracil inhibits pre-rRNA processing (Bywater et al., 
2013). While Actinomycin D is not currently used in brain cancer therapy due of its 
systemic side effects and toxic effects on mature neurons, other compounds are in the 
development.  
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2 PRESENT INVESTIGATION  
AIM OF THE STUDY  
The overall aim of this thesis was to advance our understanding of glioma tumor biology, 
and provide novel molecular insights for the clinic.   
The three specific aims were to:  
 Mechanistically investigate the role of PROX1 and what cellular signaling 
pathways it regulates in glioblastoma. 
 Determine the expression patterns and cellular localization of the NPM1 protein in 
glial tumors, and its potential role in glioma cell proliferation and apoptosis.   
 Investigate if inhibitors of the mTOR pathway affect the activity of the p53 
pathway in glioma cells. Specifically, how this may occur through modulation of 
ribosomal protein-MDM2 interaction in the setting of nucleolar stress. 
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3 RESULTS & DISCUSSION 
 STUDY I  
Decreased PROX1 levels transition glioblastoma cells into the mesenchymal 
glioblastoma gene expression subtype. 
3.1.1 Results 
Expression of PROX1 mRNA was analyzed in a combined TCGA dataset containing low 
and high-grade gliomas extracted from the GlioVis portal (http://gliovis.bioinfo.cnio.es/). 
Intriguingly, the average PROX1 mRNA expression was significantly lower in grade IV 
tumors than in grade II and III tumors. Upon survival analysis in the same dataset, a 
subgroup of cases with higher PROX1 expression was associated with a median survival 
of 67.5 months that was significantly higher than the median survival of 34.9 months in 
the subgroup with lower PROX1 levels. Subsequent analysis of the gene expression 
subtypes in grade IV gliomas associated the patient group with highest PROX1 levels to 
the classical and proneural subtypes. On the other hand, the group with low PROX1 
mRNA consisted mainly of cases of mesenchymal gene expression subtype.   
Further exploration was performed by Gene Set Enrichment Analysis (GSEA) in order to 
assess gene expression differences in a set of 45 glioblastoma cell lines in the Cancer Cell 
Line Encyclopedia (CCLE) (Barretina et al., 2012), identifying PROX1-associated gene 
ontology (GO) terms. It was revealed that cell cultures with high PROX1 expression were 
enriched with signatures for histone methylation (H3K27Me3), PDGFRB signaling, 
SOX2 targets, and positive regulation of epithelial proliferation, while cultures with low 
PROX1 expression were enriched for ESRRA-, HOXA9- and the Verhaak Mesenchymal 
glioblastoma subtype-signatures. Furthermore, an analysis of PROX1 correlated genes, in 
375 glioblastoma patients data available from TCGA, identified MARK1 as the highest 
correlated (r=0.54) gene, which encodes a serine/threonine-protein kinase involved in 
regulation of cell polarity and microtubule dynamics and proposed as a positive regulator 
of the Wnt signaling pathway (Kojima et al., 2007; Sun et al., 2001). In addition, several 
landmark genes including SEMA6A (r=0.50), ZEB1 (r=0.48) and MAP2 (r=0.46) were 
found present among the top 50 correlated genes. On the other hand, in this analysis IL15 
(interleukin 15) was identified as the most anti-correlated gene (r=-0.40), and ESR1 
(estrogen receptor (ER)-alpha) ranked among the top 20 anti-correlated genes in these 
samples (rank position 16, r= -0.35).  
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To further evaluate PROX1 expression in glioma, protein levels were measured in a panel 
of glioma cultures including the ones from the U-343 system, which is a set of cell 
cultures that were derived from a single glioblastoma (Nister et al., 1986; Nister et al., 
1987). Immunoblotting revealed that PROX1 is differentially expressed in glioma cell 
lines – undetected in U-343 MG while expressed at high levels in U-343 MGa. 
Furthermore, it was co-expressed with the glioma markers for a cancer stem cell 
phenotype, SOX2 and GFAP.  
PROX1 is a known transcription factor. To gain insights into PROX1-regulated gene 
networks in glioblastoma, and investigate the functional consequences of PROX1 
modulation, the U-343 cultures and newly generated stable cell lines thereof with 
overexpression or suppression of PROX1, were subjected to global gene expression 
analysis by RNA sequencing. Of note, the U-343 MG and U-343 MGa cultures were 
found to represent two cell phenotypes mesenchymal-like and non-mesenchymal, 
respectively (Nister et al., 1986; Nister et al., 1987). Interestingly, PROX1 modulation in 
the setting of the U-343 cultures seemed to alter these states, suggested by regulation of 
GFAP levels. On a larger scale, overexpression of PROX1 in the mesenchymal type 
glioblastoma culture U-343 MG and PROX1 suppression in the non-mesenchymal type 
culture U-343 MGa could transition these into the opposite type – defined by Verhaak et 
al. (Verhaak et al., 2010). Thus, PROX1 can regulate the transition of these transcriptional 
subtypes in a reversible manner in tumor cells derived from the same tumor. 
Based on these results, it was found that PROX1 overexpression affected regulators of the 
cell cycle, and increased the rate of cell proliferation of U-343 MG cells. Furthermore, 
this study places PROX1 under the control of the SOX2 transcription factor, and indicates 
decreased levels of both SOX2 and PROX1 in response to treatment of glioblastoma cells 
with CDK2 small molecule inhibitor CVT-313.  
Finally, experiments performed in this study identified THRAP3 as a novel interacting 
partner and potentially a co-regulator of PROX1 expression and/or protein stability.  
3.1.2 Discussion 
PROX1 was previously proposed as a predictor of survival for gliomas WHO grade II, by 
using tumor histopathology methods (Elsir et al., 2011), but whether the observed 
correlation is causative has not been shown. The study herein was aimed at bringing 
biological insights into PROX1 expression and function in glioblastoma. The results 
propose utility of PROX1 expression levels as a prognostic marker in glioblastomas, 
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distinguishing the gene expression subtypes, and PROX1 maintenance of a glial stemness 
profile and proliferation capacity with high levels of G1-cyclins.  
The inter-tumor heterogeneity observed in glioblastoma patients poses a great challenge 
to diagnosis and therapy. Moreover, cells within a single tumor exhibit distinct 
phenotypes, genotypes and epigenetic states, as it was highlighted by a recently published 
landmark single-cell transcriptome analysis (Patel et al., 2014). The study proposed 
potential plasticity among glioblastoma molecular subtypes under microenvironmental 
influences, and underscored the significance of intratumoral heterogeneity where tumors 
with higher percentage of proneural cells had better clinical outcome than those with 
intermixture of different subtypes (Patel et al., 2014). Reflecting cancer evolutionary 
dynamics, such intratumoral heterogeneity and redundant signaling pathways can also 
provide explanations for the common failures of conventional and targeted therapies to 
result in long-term remissions (Sottoriva et al., 2013).   
The expression analysis of TCGA data suggested that glioblastoma patients with tumors 
having low PROX1 mRNA levels were enriched for mesenchymal gene expression 
subtype and shorter survival. Furthermore, the transcriptional analysis of PROX1 
functional effects in cell cultures, combined with co-expression analysis in the TCGA, 
CCLE, HGCC, and single-cell RNA sequencing data from 5 tumors (Patel et al., 2014), 
describes PROX1 as a regulator of glioblastoma tumor evolution that could distinguish 
different cell populations in these heterogeneous tumors.  
Importantly, PROX1 was found to be a regulator of glioblastoma transcriptional profiles, 
as discussed earlier. According to the presented analysis of TCGA data, PROX1 
expression is increased from grade II to III, decreased in grade IV tumors, and is found 
significantly higher in proneural and classical glioblastomas than in those with 
mesenchymal profile. PROX1 could therefore mark a transitory stage in the evolution of 
gliomas, potentially similar to its role in the CNS development as a determinant of the 
neuronal and glial cell developmental paths (Elsir et al., 2012; Torii et al., 1999). A 
consensus point, emerging from a wealth of molecular profiling of glioblastomas in recent 
years is the general recognition of the two proneural and mesenchymal subtypes. It is 
believed that most glioblastomas evolve from a proneural-like precursor glioma to the 
mesenchymal gene expression subtype; for instance, via loss of NF1 that is a later event 
during tumor evolution (Ozawa et al., 2014). While detailed functions of PROX1 in 
glioma tumor evolution remains to be elucidated, it appears to regulate the transition from 
proneural/non-mesenchymal to mesenchymal profile in glioblastoma. In early or low-
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grade gliomas, one could speculate that high-PROX1 expressing cells in a tumor are 
derived from a cell of origin with stem like properties, which normally are committed to 
differentiate into oligodendrocytes (Bunk et al., 2016). In extension, glioblastomas with 
high PROX1 could be suspected to arise from oligodendrocyte precursor cells, which is 
one suggested source of glioblastomas (Lindberg et al., 2009). Given that increasing 
PROX1 levels in low-grade gliomas have been shown to correlate with increasing poor 
prognosis (Elsir et al., 2011), PROX1 could here be speculated to drive an increased 
stemness and proliferation phenotype during tumor cell evolution. While in glioblastomas 
loss of PROX1 would occur during a later stage of tumor cell evolution. As shown, 
increasing PROX1 levels in cells will increase stemness gene expression, proliferation 
and tumor formation capacity  (Figure 3). Intuitively, this should coincide with a 
clinically less favorable situation. However, it is low PROX1 levels that correlate with 
shorter survival in glioblastoma. Per a tumor cell evolution model of tumors with intra-
tumoral heterogeneity the mesenchymal subtype expression profile based on bulk tumor 
measurements could be reflected by tumors that have a higher fraction of cells that have 
progressed in a tumor cell evolution perspective. These different tumor cell populations 
raise the question of which are more relevant to target, the more progressed cells, the 
more stem like cells or both? 
 
Figure 3. A hypothetical model for PROX1 in glioma tumor evolution. 
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radiation response in an in vivo model of glioblastoma induced apoptotic gene expression 
program and suppressed cell cycle progression (Halliday et al., 2014). This response was 
reported to alter the gene expression profile from proneural to mesenchymal. In 
agreement, reduced p53 level and increased rate of cell proliferation coincided following 
PROX1 overexpression in U-343 MG cells with mesenchymal to non-mesenchymal 
transition. Of note, a revised view on p53 mechanisms of tumor suppression suggests p53 
inhibition of stem cell self-renewal (Meletis et al., 2006),  as well as blocking 
reprogramming of differentiated cells into stem cells (Bieging et al., 2014). Thus, it 
would be of interest to further investigate PROX1 regulation of stemness gene signature 
in relation to decreased p53 protein levels observed in this study.   
An integrated analysis of G-CIMP positive tumors associated this phenotype to IDH1 
mutations in low- and intermediate-grade gliomas, and upregulation of genes related to 
cell metabolism and positive regulation of macromolecules (Noushmehr et al., 2010). 
Furthermore, an EMT/PMT shift may be dependent on metabolism alterations, as it was 
recently shown (Shaul et al., 2014). Given that PROX1 could regulate metabolic 
processes, the expression differences observed here might reflect metabolic adjustments 
by the tumors as they evolve from low-grade to high-grade. In line with the Warburg's 
effect, it could be hypothesized that more proliferative non-mesenchymal tumors with 
higher PROX1 mRNA expression preferentially convert glucose to lactate, whereas 
mesenchymal tumor cells could use the oxidative phosphorylation pathway in a more 
energy-efficient manner.  
The performed analysis herein places PROX1 downstream of the pluripotency and 
neurodevelopmental factor SOX2, which has been suggested to be a driver of a cancer 
stem cell behavior, and gliomagenesis (Hagerstrand et al., 2006; Suva et al., 2014). The 
GSEA identified a signature for trimethylation of histone 3 on lysine 27 (H3K27me3), 
associated with gene silencing. The methylation of H3K27 is known to be mediated by 
Enhancer of Zeste homolog 2 (EZH2) (Czermin et al., 2002). EZH2 is frequently 
amplified or overexpressed in a number of cancer types including glioblastoma (Lee et al., 
2008), and has a canonical role in gene silencing through H3K27me3 (Vire et al., 2006). 
EZH2 is strongly upregulated in Ewing embryonic tumors of undifferentiated 
mesenchymal origin, and blockade of EZH2 was reported to induce expression of several 
hallmark epithelial and neuroectodermal differentiation genes including SOX11 and 
GFAP in cell lines (Richter et al., 2009). In conjunction with this, SOX4, EZH2 and 
HDAC3 together form a co-repressor complex that binds to the miR-31 promoter, causing 
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repression of miR-31 through an epigenetic mark by H3K27me3 and by histone 
acetylation in esophageal cancer cells (Koumangoye et al., 2015). Furthermore, PROX1 
and HDAC3 interact in a co-repressor module, which co-occupy extensive genomic 
binding sites, revealing a metabolic signature in the mouse liver (Armour et al., 2017). 
Therefore, PROX1 involvement under other glioblastoma oncogenes that functionally 
overlap with SOX2 such as EZH2 should be pursued.  
We should also recall that the higher proliferative capacity of PROX1 overexpressing 
cells in vitro – also suggested recently by others (Xu et al., 2017), may not reflect the in 
vivo situation where a mixture of cells is more strictly controlled in their niche. In the 
tumor tissue PROX1 expressing cells may exist in a more stem-like resting state, but with 
potential to proliferate. In support of this notion, a previous investigation by Patel et al. 
observed a striking contrast between the activity of cell cycle program in the in vitro 
glioblastoma models scoring almost 100% positive for the “cell cycle module”, and the 
single-cell transcriptome of tumors, where it ranged from just 1.4% to 21.9% proliferating 
cells (Patel et al., 2014).  
It was reported that the EMT status is associated with worse overall survival in 
glioblastomas, ovarian and gastric cancers but intriguingly no association was found in 
other carcinoma types investigated (Tan et al., 2014). The authors developed a generic 
EMT score based on cancer specific transcriptomic EMT signatures and used it to 
establish an EMT spectrum across various cancers, showing that glioblastomas primarily 
have mesenchymal gene expression pattern (Tan et al., 2014). Another recent study 
evaluated the expression of 12 glioblastoma signature genes (6 representative markers for 
each proneural and mesenchymal subtype), with the aim to develop a clinically applicable 
method for differentiating these transcriptional subtypes. A predominant “metagene 
score”” was calculated by subtracting the “mesenchymal score” (as the average value of 
ΔΔCt of 6 markers) from the “proneural score” in glioma samples of different grades as 
analyzed by quantitative RT-PCR, which was able to distinguish proneural/mesenchymal, 
and decreased in cases of tumor recurrence and malignant transformation (Murata et al., 
2015). Moreover, the mesenchymal score showed a positive correlation with the tumor 
grade, whereas the proneural score did not (Murata et al., 2015).  Interestingly, a survey of 
PROX1 correlation with these markers in TCGA data from 206 glioblastoma patients 
(Goudarzi KM et al., unpublished data) shown in Figure 4, suggests that PROX1 mRNA 
levels alone is sufficient to distinguish between these markers, thus allowing such mRNA 
quantification in a feasible and clinically straightforward manner. 
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Figure 4. PROX1 correlation with selected proneural /mesenchymal markers in TCGA data 
Collectively, PROX1 may constitute a promising and a clinically applicable tool to 
distinguish mesenchymal from non-mesenchymal tumors, and potentially assess the level 
of heterogeneity within tumors. Also, the significance of PROX1 in malignant 
transformation merits further investigation.  
Future experimental inquiries should unravel additional pieces to the molecular puzzle 
that underlies PROX1 function, not only in gliomas and other cancers but also in healthy 
tissues, which in turn may help direct us towards cancer prevention, earlier diagnosis, 
improved prognosis, and novel avenues for therapeutic interventions. 
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STUDY II 
NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and 
maintain nucleolar shape. 
3.2.1 Results 
NPM1 protein levels and subcellular localization were initially assessed in a panel of 60 
gliomas (16 grade I, 16 grade II, 15 grade III, & 13 grade IV) by immunohistochemical 
(IHC) staining, using a previously validated monoclonal antibody (Holmberg Olausson et 
al., 2014). The IHC analysis revealed nucleolar staining of NPM1 in the tumors of all 
grades, displaying an overall increase in the signal intensity from grade I to IV 
astrocytomas that was significant when comparing grade I and IV tumors (p= 0.000245, 
Chi square test). Moreover, grade IV tumors were distinguished with a clear increase in 
nuclear staining of NPM1 in 12 out of 13 cases. Consistently, NPM1 was detected in both 
nucleoli and nucleoplasm of a panel of glioblastoma cell lines tested. Moreover, IHC 
analysis revealed Npm1 protein in the nucleoli of both undifferentiated mice NSCs 
cultured as spheres and differentiated NSCs grown as monolayers, while in addition a 
more generalized nucleoplasmic staining was noted in the more undifferentiated cells.  
To explore NPM1 function in glioma, NPM1 was depleted using siRNA, resulting in a 
transformed nucleolar morphology in cells, assessed by phase contrast microscopy, 
Acidic Toluidine Blue O and silver (AgNOR) staining assays of the nucleoli, and 
immunofluorescence (IF) staining of nucleolar protein fibrillarin.  Of note, the nucleolar 
re-organization in NPM1 depleted cells was not akin to structural changes induced by 
inhibitors of RNA polymerases I and II, Actinomycin D (5nM) and DRB (25 μM) 
treatment of the cells, respectively, which were used in the analysis as controls. Moreover, 
the siRNA-mediated knockdown of NPM1 did not cause a major alteration in the cell 
cycle distribution, suggesting that most of NPM1 protein is not needed to support 
proliferation of the glioma cells.  
We hypothesized that NPM1 depletion could sensitize cells to apoptosis and in order to 
test this glioma cultures were treated with siNPM1 as well as Actinomycin D. The NPM1 
depletion alone did not induce evident signs of apoptosis, but decreased the survival of 
Actinomycin D treated cells, as indicated by increased positivity for cleaved caspase-3 
protein in IF analysis.  
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In addition, NPM1 depletion sensitized U251MG glioma cells to concentrations of 
chemotherapeutic drugs Temozolomide and 5-Fluorouracil, but did not have much of an 
effect in the U343MGa Cl2:6 cell line. 
Finally, siNPM1 treatment rendered glioma cells more sensitive to the detrimental effects 
of linker histone H1.5 knockdown, assessed by increased positivity for cleaved caspase-3 
in IF analysis. The histone H1.5 is a key component of chromatin architecture that binds 
NPM1 (Holmberg Olausson et al., 2014), and this association was confirmed using a 
nuclear complex co-IP in the presented study II. 
3.2.2 Discussion 
Consistent with other recent reports (Chen et al., 2015; Kuo et al., 2015), high expression 
of NPM1 in astrocytic glioma samples (grades III-IV) was confirmed by histochemical 
analysis performed herein with increasing intensity in glioblastoma tissues. Of note, high 
NPM1 expression has been associated with poor survival in glioma patients (Chen et al., 
2015; Kuo et al., 2015). Secondly, the study evaluated subcellular localization pattern of 
NPM1, and marked a nucleoplasmic staining in glioblastomas, in addition to the nucleolar 
staining, which was unitedly observed in both grade III and grade IV tumors. One 
interesting possible explanation for the presence of nucleoplasmic NPM1 observed in 
glioblastoma tissues (besides its overexpression and nucleolar spillover), consistent with 
the cell lines, is the change of chromatin landscape in the highest-grade tumors. Based on 
our observations, NPM1 should not be considered as an exclusive nucleolar marker. 
NPM1 involvement in higher-order chromatin organization, and interactions with factors 
such as linker histone H1.5 has been previously reported (Holmberg Olausson et al., 
2014; Li et al., 2012). Earlier investigations indicated H1.5 in the maintenance of 
condensed chromatin and found enrichment of genes involved in apoptosis following 
H1.5 depletion (Li et al., 2012). It was hypothesized that NPM1 could maintain the 
structural organization of the cell nucleoli via interaction with chromatin remodeling 
factors such as H1.5. 
Depletion of NPM1 triggered evident nucleolar distortion. Furthermore, NPM1 depletion 
(by itself) sensitized glioma cell line U251MG to concentrations of Temozolomide and 5-
Fluorouracil, but such pro-survival effect was not as apparent in other cell lines tested. 
The U251MG cells have a higher degree of aneuploidy that could be an underlying reason 
for higher sensitivity of these cells to drug-induced DNA damage. It should also be noted 
that all three glioma lines used in these experiments appear rather drug-resistant. 
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Therefore, it is of interest to explore these findings in a larger panel of glioma cells that 
also include cultures in NSC condition. 
Unlike NPM1, depletion of H1.5 induced cell death in all cell lines tested. Intriguingly, 
the cytotoxic effect was more dramatic when the two proteins were co-depleted, which 
points to a pro-survival role for NPM1 connected to the maintenance of genome integrity 
in glioma.  
Taken together, NPM1 is upregulated in glioblastoma tissues and cell lines, displaying a 
pattern of distribution non-exclusive to the nucleoli, and may promote viability of stressed 
cells during glioma pathogenesis, which merits further investigation.   
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STUDY III 
mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and 
MDM2 levels. 
3.3.1 Results 
This study investigated the p53 response to nucleolar stress concurrent with inhibition of 
the mTOR pathway in osteosarcoma and glioblastoma cells with wild type p53. The 
results revealed that both synthetic mTOR inhibitors such as Temsirolimus or PP242, and 
“natural” inhibitors such as Rapamycin, Resveratrol or caffeine could impair p53 
stabilization induced by low dose of drug Actinomycin D (5 nM). Specifically, the protein 
level of p53 transcriptional target p21 was also reduced, corresponding to the p53 decline.  
To assess the biological consequences of p21 inhibition as a readout for nucleolar stress 
and impairment of p53 activation, the cells were treated with different combinations of 
Rapamycin (100 nM, high concentration), Actinomycin D (5 nM, low concentration), and 
Nutlin-3 (10 μM) and the drug-induced morphological effects were monitored using light 
microscopy. Nutlin-3 is a potent small-molecule that restores p53 activity via disruption 
of p53-MDM2 interaction (Vassilev et al., 2004) and is not linked with nucleolar stress. It 
therefore served as a control in these experiments. Visual inspection of the cell cultures 
and a comparison of cell viability by MTT assay suggested that combination of 
Rapamycin and Actinomycin D had less potent growth inhibitory effect than Rapamycin 
plus Nutlin-3. Further investigation revealed an increase in the percentage of cells in S-
phase corresponding to Rapamycin and Actinomycin D co-treatment compared with 
Actinomycin D treatment alone, whereas no major difference in cell cycle distribution 
was observed with Rapamycin and Nutlin-3 versus Nutlin-3 only. Note that, treatment of 
cells with Actinomycin D and Nutlin-3 applied as single agents resulted in a cell cycle 
profile with accumulated cells in G1 and G2/M phases, and fewer cells in S-phase, 
compared to DMSO-treated control. 
Rapamycin may interfere with p53 protein stabilization/activity via inhibition of mTOR 
pathway and a subsequent reduction in expression of RPs, specifically MDM2 binding 
protein RPL11 (similarly RPL5). To test this hypothesis, p53 and MDM2 protein half-life 
assays were coupled with the analysis of ribosomal protein binding to MDM2 using in 
vivo labeling and immunoprecipitation. We could conclude that reduced levels of RPL11 
and binding of RPL11 to MDM2 may be of importance, but it appeared as this was not 
the only explanation. For example, we noted that Rapamycin treatment resulted in 
increased levels of endogenous MDM2 and an inhibition of its phosphorylation at Ser166. 
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3.3.2 Discussion 
Study III assessed the utility of combinatorial anti-cancer strategies including mTOR 
inhibitor compounds and those that trigger nucleolar stress, and investigated the interplay 
of mTOR and p53 pathways in this setting. Because Rapamycin analogues or combined 
mTOR/PI3K inhibitors have shown promise in clinical trials for several tumor types 
including glioma, the experiments combined this class of drugs with small molecules that 
directly interfere with rDNA transcription or p53 hyper-activating drugs. Surprisingly, the 
pre-treatment of glioma cells with Rapamycin was found to markedly blunt p53 activation 
following a low dose of Actinomycin D but not when using the MDM2 inhibitor Nutlin-3. 
Nutlin-3 disrupts binding between p53 and MDM2 and does not require ribosomal 
proteins for its effects to activate p53. 
The results from this study did not indicate any synergism in growth inhibitory effects of 
the simultaneous drug treatments. On the contrary, co-treatments with Rapamycin and 
Actinomycin D increased the number of BrdU+ cells, coinciding with a change in cell 
cycle distribution towards more cells in the S phase, compared to Actinomycin D alone. 
In addition, induction of p21 was attenuated when cells were co-treated with the cytostatic 
concentration of the drugs used in the experiments.  Importantly, mTOR inhibitors did not 
blunt the p53 response to Nutlin-3 treatment to the same extent as in the case of 
Actinomycin D.  
Following these observations, experiments were designed to determine the mechanism(s) 
behind apparent mTOR-p53 pathway crosstalk based on the prevalent indirect model, 
where cellular localization of p53/MDM2-interacting factors could determine p53 levels. 
Accumulating evidence indicate that p53 is induced following impaired rRNA synthesis, 
disruption of rRNA modification and processing, or an imbalance of RPs. The prevalent 
mechanism put forward for p53 activation is through the RP-MDM2-p53 axis. In brief, 
excessive amount of RPs caused by an inhibition of rRNA synthesis, or availability of 
free ribonucleoprotein intermediates or unprocessed rRNA to bind MDM2 could lead to 
p53 stabilization (Deisenroth and Zhang, 2010). 
An established factor as such is the essential component of 5S RNP complex RPL11, 
which contributes to p53 stabilization following nucleolar stress (Goudarzi and 
Lindstrom, 2016; Sloan et al., 2013). Notably, de novo synthesis of RPL11 is required for 
this effect. It was shown that Rapamycin suppresses mitogen and amino acid induced 
activation of mTOR and translation of 5´TOP mRNAs, which is mediated in some cases 
by S6K (Gentilella et al., 2015). Given that RPL11 is translated as a 5´TOP mRNA, it was 
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hypothesized that treatment of cancer cells with inhibitors of the mTOR pathway leads to 
reduced synthesis of RPL11, and thereby p53 destabilization in this setting. Notably, these 
observations may also be extended to other compounds inhibiting mTOR including 
caffeine and wortmannin, and may explain effects on p53, ageing and cancer. 
It was found that depletion of RPL11 mimicked the effect of rapamycin treatment with 
regards to inhibition of p53 response to nucleolar stress. However, rapamycin treatment 
did not reduce RPL11 and p53 levels in a consistent manner in the cell lines tested. 
Notably, rapamycin treatment increased the endogenous level of MDM2, although 
phosphorylation of MDM2 at Ser-166 was inhibited. Therefore, other mechanisms should 
be involved that merit further research.   
Taken together, these results indicate that Rapamycin among other inhibitors of mTOR 
pathway and ribosome biogenesis, interfered with p53 protein stabilization following 
nucleolar stress in osteosarcoma and glioma cell lines; a finding that could be important in 
the design of clinical trials involving Rapamycin-like compounds. The results also 
underscore the complexity of mTOR–p53 interplay in cancer, which should be further 
investigated.  
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4 SIGNIFICANCE AND FUTURE PERSPECTIVES 
How can we treat gliomas more effectively? Conventionally, gliomas have been classified 
into oligodendroglioma (WHO grades II–III), oligoastrocytoma (WHO grades II–III), and 
astrocytoma (WHO grades I–IV). However, a lack of consensus definition for gliomas as 
a larger class of histologies has made it difficult to compare and evaluate results from 
different studies (Ostrom et al., 2014). Advancements in molecular biomarkers of glioma 
entities will pave the way to improved treatment approaches in neurooncology. 
Specifically, glioblastomas feature distinct phenotypic, genotypic, and epigenetic states 
forming a complex ecosystem. Studies of molecular biomarkers are pivotal in 
glioblastoma research as the existing biomarkers investigated so far are not robust enough 
to implement in the clinic on a stand-alone basis. Moreover, of the potential biomarker 
genes studied in recent years, for instance via mining of databases such as TCGA, none 
has shown enough specificity to predict the complex course of disease progression and 
patient outcome. Therefore, the current view is that detailed characterization of molecular 
signatures in glioblastoma and a more individual therapeutic approach could provide 
better alternatives for the clinic and facilitate development of new therapies against 
glioblastoma.   
Remarkably, the gut microbiota has emerged in recent years in pathogenesis of different 
diseases including cancer, as well as in response to therapies (Zitvogel et al., 2017). It was 
reported that acetate synthesized by the intestinal bacteria, is a potential oncometabolite 
(as opposed to butyrate) that supports the growth of human glioblastomas and brain 
metastases (Mashimo et al., 2014; Zitvogel et al., 2017). Moreover, with the accumulating 
evidence on the gastrointestinal tract and brain bidirectional communication involving 
immune mechanisms (Zitvogel et al., 2017), it is not farfetched to expect that similar risk 
factors that cause disequilibria in intestinal bacteria through our lifespan could contribute 
to the development of covert “cancerized fields” that eventually manifest in a specific 
cancer diagnosis.  
In light of the aforementioned evidence on microbiota–gut–brain axis, one can anticipate 
that future research will bring more attention to PROX1 involvement in maintenance of 
stemness features as well as energy homeostasis in tissues identifying common risk 
factors that may connect gliomas with ‘metabolic inflammation’ and the gastrointestinal 
malignancies. The findings in the study I in this thesis point to PROX1 participation in 
diverse regulatory programs central to glioma biology. Indeed, intriguing similarities were 
observed between the PROX1-related molecular circuitry in glioma and the previous 
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reports from gastric and colorectal cancers (Laitinen et al., 2017; Ragusa et al., 2014). The 
RNA-seq based expression analysis of glioblastoma cultures predicted PROX1 
involvement in glycolysis, inflammatory response, adipogenesis, and the regulation of 
NF-kB pathway. Meta-analyses of genome-wide association studies have associated 
single-nucleotide polymorphism in PROX1 with fasting glycaemia and type2 diabetes 
mellitus (DIAGRAM et al., 2014; Dupuis et al., 2010), and reduced PROX1 expression 
was reported to alter β-cell insulin secretion, thereby conferring susceptibility to type2 
diabetes (Lecompte et al., 2013). Strikingly, pre-diagnostic hyperglycaemia and diabetes 
were linked to a lower risk of developing glioma in a recent meta-analysis (Zhao et al., 
2016), and excess glucose consumption by the preclinical tumor was suggested to 
paradoxically account for the inverse association between blood glucose and glioma 
(Schwartzbaum et al., 2017). Alternatively, hyperglycaemia could induce apoptosis and 
inhibit proliferation of neural stem cells, possibly via activation of JNK/p38 MAPK 
pathways and the delay of G1-S transition in the cells (Chen et al., 2013a; Schwartzbaum 
et al., 2017), thereby conferring protection against glioma.  
Further, NF-kB has emerged in recent years to integrate metabolism and inflammation 
with profound implications for oncogenesis (Tornatore et al., 2012), and its activation was 
recently associated to PROX1 in glioblastoma cells (Xu et al., 2017). Therefore, 
considering the aforementioned observations, it is of great interest to address PROX1 
expression and function in healthy versus inflamed and tumor tissues with regards to 
energy homeostasis and immunity to find viable indications for cancer prevention, 
improved diagnosis and therapy. Moreover, since PROX1 is involved in regulation of 
metabolic clock gene expression (Dufour et al., 2011), and perturbed clock is linked to 
malignancies including gliomas (Chen et al., 2013b; Sahar and Sassone-Corsi, 2009); a 
possible role for PROX1 in clock-related differences between tumors and healthy cells 
should not be ignored. 
On a related note, it was recently reported that Rapamycin upregulates triglycerides in 
hepatocytes by inhibiting Prox1 expression in hepatocytes, suggesting that the mTOR 
pathway is involved in the regulation of triglycerides by controlling Prox1 levels (Kwon 
et al., 2016). Specifically, Rapamycin affects Prox1 protein but not its transcript. 
Rapamycin upregulated the amount of triglyceride and downregulated the expression of 
Prox1 in HepG2 cells by reducing protein half-life while the transcript levels remained 
unaffected (Kwon et al., 2016). Whether such regulation exists in the brain has not been 
explored, and would be of interest to investigate in the context of gliomas. 
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The epidemiology of glioblastomas indicates increasing incidence in adults with age, 
slightly higher occurrence in men, and among the most conclusive prognostic markers are 
age of onset, the extent of tumor resection and Karnofsky performance status (Ostrom et 
al., 2014; Stupp et al., 2014). Unlike other solid tumor types, glioblastomas rarely 
metastasizes to other organs. On the contrary, brain metastasis occur from gastrointestinal 
cancers, which are on the rise in Sweden (Smedby et al., 2009) and worldwide, with an 
underestimated frequency due to a lack of routine brain scans and overlooked 
asymptomatic lesions; for a systematic review of 74 reported studies with brain metastasis 
originated from gastrointestinal cancer see (Esmaeilzadeh et al., 2014).  It was revealed 
from the data available for 2538 patients with brain metastasis that 2028 patients 
(79.90%) had colorectal cancer, followed by 233 patients (9.18%) with liver and 148 
patients (5.83%) with gastric malignancies.  
A wealth of research in recent years has underscored disruption of ribosome biogenesis or 
nucleolar stress in cancer pathogenesis. Current research is focused on how cancer cells 
maintain high efficiency and accuracy of ribosome synthesis and an important question is 
how ribosome biogenesis is connected to stress responses and cell cycle control. 
However, the mechanisms sensing nucleolar stress and how anti-proliferative p53 is 
activated following nucleolar stress are not fully understood, but should be resolved in the 
coming years. The challenges that cancer cells meet due to their high demand of ribosome 
manufacturing for sustained tumor growth, and their mechanisms of quality control 
surveillance can be exploited for the design of novel targeted therapeutics.   
Despite the large amount of research efforts that has linked the mTOR pathway to cell 
growth and survival, there has been a limited progress for mTOR inhibitors in the clinical 
trials. Furthermore, it is inherently challenging to determine the function of particular 
ribosomes in a cell, and thus investigating the effects of the drugs on fundamental cell 
processes such as ribosome biogenesis and p53 activation, for example, by using 
biochemical analysis. Indeed, an advanced understanding of the crosstalk between mTOR 
and p53 pathways is required for the utility of mTOR inhibitors as therapeutic options, 
specifically in combinatorial strategies to overcome drug resistance and enhance efficacy. 
The main finding in the study III was that the natural and synthetic mTOR inhibitors 
could blunt the p53 response to nucleolar stress induced by chemotherapeutic agents such 
as Actinomycin D. First and foremost, this observation might have significance for the 
design of various combinatorial anti-cancer drug treatment regimens using mTOR 
inhibitors. In other words, the simultaneous inhibition of the p53-dependent nucleolar 
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pathway – likely a disadvantage in combinatorial treatments must be considered in this 
setting. Secondly, similar effect of physiologically relevant concentrations of natural 
mTOR inhibitors, for example caffeine on basal levels of p53 and or p21 in heavy coffee 
drinkers merits further inquiry.  
This thesis explored the significance of two molecular biomarkers PROX1 and NPM1 in 
glioblastoma, and investigated the interplay of p53 and mTOR pathways via testing the 
synergism of a range of chemotherapeutic agents. Looking ahead, extensive progress is 
envisioned during the coming years in our understanding of glioma tumor biology. In 
unison, it is hoped that studies presented in this thesis will bring new perspectives on 
biomarkers of high-grade gliomas, provide some insight into the possible future use of 
mTOR inhibitors and related compounds in glioma, and contribute to future 
improvements in the lives of glioma patients.    
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